Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 5/20 | 0.43 |
| ▸ | PARP1 | P09874 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5779341 | 0.83 | PARP1 (0.47) | SLC40A1PARP1ALDH1A1GRIN2BCHRNA7 | |
| SCHEMBL5775830 | 0.80 | SLC40A1 (0.47) | SLC40A1PARP1ALDH1A1KDM4ECHRNA7 | |
| SCHEMBL15160678 | 0.75 | KMT2A (0.48) | ALDH1A1KDM4EPOLBOPRD1 | |
| SCHEMBL13327274 | 0.73 | POLB (0.52) | ALDH1A1POLBALOX15 | |
| SCHEMBL22397770 | 0.73 | POLB (0.52) | ALDH1A1POLBALOX15 | |
| SCHEMBL4717949 | 0.73 | KMT2A (0.46) | POLB | |
| SCHEMBL5656451 | 0.73 | KDM4E (0.53) | SLC40A1ALDH1A1KDM4EPOLBALOX15 | |
| SCHEMBL5773822 | 0.71 | HTR6 (0.45) | SLC40A1ALDH1A1KDM4ECHRNA7 | |
| SCHEMBL5776558 | 0.70 | HRH1 (0.45) | ALDH1A1POLBOPRD1 | |
| SCHEMBL25330425 | 0.70 | POLB (0.50) | ALDH1A1POLBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343780-B1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM PLC (GB) | 2006-09-20 | — | — | EP | disclosed |
| US-20040077655-A1 | Piperazine derivatives for treatment of bacterial infections | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-22 | — | — | US | disclosed |
| EP-1343780-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM PLC (GB) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002050061-A1 | PIPERAZINE DERIVATIVES FOR TREATMENT OF BACTERIAL INFECTIONS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077655-A1 | Piperazine derivatives for treatment of bacterial infections | MYD88, THPO, PIGO | SLC40A1 586/4885PARP1 1993/4885ALDH1A1 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.